At the European Cancer Congress (ECC) 2015, Wolfgang Janni, MD, PhD University Hospital Ulm, Ulm, discusses the interim analysis of the DETECT study, which was designed to evaluate the prognostic and predictive value of HER2-status of circulating tumour cells in patients with metastatic breast cancer.
Login to continue
Members
Create Account
Create your own personal healthcare feed, full of the latest content from across our divisions.
Register
![EMJ Oncology 10 [Supplement 6] 2022 Feature Image](https://emj.emg-health.com/wp-content/uploads/sites/2/2022/03/EMJ-Oncology-10-Supplement-6-2022-Feature-Image-940x563.jpg)
![EMJ Oncology 10 [Supplement 5] 2022 Feature Image](https://emj.emg-health.com/wp-content/uploads/sites/2/2022/03/EMJ-Oncology-10-Supplement-5-2022-Feature-Image-1-940x563.jpg)